Jupiter Neurosciences Introduces Nugevia™ MND: A Cognitive Health Supplement Leveraging Clinically Validated Neuroscience
Jupiter Neurosciences (NASDAQ: JUNS) has launched Nugevia™ MND, a cognitive health supplement combining their proprietary JOTROL™ resveratrol technology with NovaSOL® Curcumin. The product targets the $8 trillion longevity and wellness markets and will be available Fall 2025.
The supplement aims to enhance cognitive performance and neuroprotective health through multiple pathways, including reducing oxidative stress and inflammation. CEO Christer Rosén emphasized the personal significance of the product, citing family experiences with Alzheimer's and Parkinson's diseases.
Nugevia MND represents a strategic move to generate high-margin revenue while complementing Jupiter's pharmaceutical pipeline. The company plans to leverage consumer usage data alongside biomarker data from their upcoming Phase II Parkinson's disease trial to inform future cognitive health programs.
Jupiter Neurosciences (NASDAQ: JUNS) ha lanciato Nugevia™ MND, un integratore per la salute cognitiva che combina la loro tecnologia proprietaria JOTROL™ a base di resveratrolo con la curcumina NovaSOL®. Il prodotto è rivolto ai $8 trilioni di mercati della longevità e del benessere e sarà disponibile nell'autunno 2025.
L'integratore punta a potenziare le prestazioni cognitive e la salute neuroprotettiva attraverso percorsi multipli, tra cui la riduzione dello stress ossidativo e dell'infiammazione. Il CEO Christer Rosén ha sottolineato il valore personale del prodotto, citando esperienze familiari con l'Alzheimer e il Parkinson.
Nugevia MND rappresenta una mossa strategica per generare ricavi ad alto margine mantenendo un ruolo complementare alla pipeline farmaceutica di Jupiter. L'azienda intende sfruttare i dati d'uso dei consumatori insieme ai biomarcatori raccolti nel prossimo trial di Fase II sulla malattia di Parkinson per orientare i futuri programmi sulla salute cognitiva.
Jupiter Neurosciences (NASDAQ: JUNS) ha lanzado Nugevia™ MND, un suplemento para la salud cognitiva que combina su tecnología propietaria JOTROL™ de resveratrol con la curcumina NovaSOL®. El producto apunta a los $8 billones de los mercados de longevidad y bienestar y estará disponible en el otoño de 2025.
El suplemento busca mejorar el rendimiento cognitivo y la protección neurodegenerativa mediante múltiples mecanismos, incluida la reducción del estrés oxidativo y la inflamación. El CEO Christer Rosén destacó la importancia personal del producto, citando experiencias familiares con el Alzheimer y el Parkinson.
Nugevia MND supone un movimiento estratégico para generar ingresos de alto margen, complementando a la vez la cartera farmacéutica de Jupiter. La compañía planea aprovechar los datos de uso de los consumidores junto con los biomarcadores de su próximo ensayo de Fase II sobre la enfermedad de Parkinson para orientar futuros programas de salud cognitiva.
Jupiter Neurosciences (NASDAQ: JUNS)가 Nugevia™ MND를 출시했습니다. 이 인지 건강 보충제는 자체 개발한 JOTROL™ 레스베라트롤 기술과 NovaSOL® 커큐민을 결합한 제품으로, 8조 달러 규모의 장수·웰니스 시장을 겨냥하며 2025년 가을에 출시될 예정입니다.
이 보충제는 산화 스트레스와 염증 감소 등 여러 경로를 통해 인지 기능 향상 및 신경 보호 효과를 목표로 합니다. CEO 크리스터 로센(Christer Rosén)은 알츠하이머와 파킨슨병을 겪은 가족 이야기를 언급하며 이 제품의 개인적 의미를 강조했습니다.
Nugevia MND는 고마진 수익을 창출하는 전략적 조치이자 Jupiter의 제약 파이프라인을 보완하는 제품입니다. 회사는 소비자 사용 데이터와 곧 시작될 파킨슨병 2상 임상시험(Phase II)에서 얻을 생체지표 데이터를 결합해 향후 인지 건강 프로그램 개발에 활용할 계획입니다.
Jupiter Neurosciences (NASDAQ: JUNS) a lancé Nugevia™ MND, un complément pour la santé cognitive qui associe leur technologie propriétaire JOTROL™ au resvératrol et la curcumine NovaSOL®. Le produit vise les marchés de la longévité et du bien‑être estimés à 8 000 milliards de dollars et sera disponible à l'automne 2025.
Ce complément a pour objectif d'améliorer les performances cognitives et la protection neuronale par plusieurs voies, notamment en réduisant le stress oxydatif et l'inflammation. Le PDG Christer Rosén a souligné la portée personnelle du produit, évoquant des cas d'Alzheimer et de Parkinson dans sa famille.
Nugevia MND constitue une démarche stratégique pour générer des revenus à forte marge tout en venant compléter la pipeline pharmaceutique de Jupiter. La société compte exploiter les données d'utilisation des consommateurs ainsi que les biomarqueurs issus de son prochain essai de Phase II sur la maladie de Parkinson pour orienter ses futurs programmes de santé cognitive.
Jupiter Neurosciences (NASDAQ: JUNS) hat Nugevia™ MND auf den Markt gebracht, ein Nahrungsergänzungsmittel für die kognitive Gesundheit, das ihre proprietäre JOTROL™-Resveratrol-Technologie mit NovaSOL®-Curcumin kombiniert. Das Produkt zielt auf die 8 Billionen-Dollar großen Märkte für Langlebigkeit und Wellness und wird im Herbst 2025 verfügbar sein.
Das Supplement soll die kognitive Leistungsfähigkeit und den neuroprotektiven Gesundheitszustand über mehrere Pfade verbessern, unter anderem durch Verringerung von oxidativem Stress und Entzündungen. CEO Christer Rosén betonte die persönliche Bedeutung des Produkts und verwies auf familiäre Erfahrungen mit Alzheimer und Parkinson.
Nugevia MND stellt einen strategischen Schritt dar, um margenstarke Umsätze zu generieren und gleichzeitig die pharmazeutische Pipeline von Jupiter zu ergänzen. Das Unternehmen plant, Verbraucherdaten zur Nutzung zusammen mit Biomarkerdaten aus der bevorstehenden Phase-II-Studie zur Parkinson-Krankheit zu nutzen, um künftige Programme zur kognitiven Gesundheit zu informieren.
- Strategic entry into the $8 trillion longevity and wellness markets
- Product leverages clinically validated JOTROL technology with proven NovaSOL Curcumin
- High-margin revenue potential through direct-to-consumer sales
- Synergistic approach combining consumer product data with Phase II trial insights
- Product revenue generation won't begin until Fall 2025
- Entering highly competitive supplement market with no proven market share
MND combines proprietary resveratrol-based platform and NovaSOL® Curcumin to enhance cognitive performance and support neuroprotective health
Jupiter, Florida, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, today introduced Nugevia™ MND, a scientifically formulated supplement designed to protect and enhance cognitive function and support overall brain health. MND addresses the surging consumer demand for clinically validated cognitive wellness solutions, opening up significant market opportunities in the rapidly growing
Innovative CNS Science, Dual-Purpose Potential
Nugevia MND uniquely combines Jupiter’s proprietary JOTROL™ resveratrol technology—demonstrated to significantly improve bioavailability and central nervous system penetration—with NovaSOL® Curcumin, a highly bioavailable curcumin formulation proven effective in supporting cognitive resilience and neuroprotection. This innovative pairing targets multiple neuroprotective pathways, including reducing oxidative stress, inflammation, and supporting synaptic plasticity, thereby promoting enhanced cognitive health.
"We’ve worked extensively on our third, and in my opinion the most important, product in the Nugevia™ launch. It is my pleasure to introduce MND to the healthspan and longevity community,” stated Christer Rosén, Chairman and CEO of Jupiter Neurosciences. “My mother passed away from Alzheimer’s Disease making this particular product one that holds a deep sense of obligation and importance to me. Additionally, Jupiter’s former CFO ultimately lost his fight to Parkinson’s Disease. This is personal, this is important and based on our JOTROL pharmaceutical pre-clinical and clinical date we are here to bring what we believe is the best cognition product to the market.”
“The introduction of Nugevia MND represents a strategic step in leveraging our CNS therapeutic expertise within the consumer health market,” added Rosén. “Importantly, learnings from consumer use of MND, combined with biomarker data anticipated from our upcoming Phase II Parkinson’s disease trial, will provide valuable insights to inform our future cognitive health programs. What is the purpose of all the new ways with early detection of these progressive diseases if there is no good way to prevent them, stop them, or significantly slow them down? We are optimistic that our clinical studies will back up my belief that we have again cracked the code and MND is the solution.”
Strategic Insight, Expanded Potential
Nugevia MND is poised to generate high-margin revenue by targeting adults seeking to maintain and enhance cognitive performance, particularly amidst aging populations increasingly impacted by cognitive decline. The product also strategically complements Jupiter’s therapeutic pipeline, creating synergies between consumer and pharmaceutical segments.
Key scientifically supported benefits of Nugevia MND include:
- Enhanced memory, clarity, and executive function
- Reduction in neuroinflammation and oxidative stress
- Support for mitochondrial function in brain cells
- Potential protective effects against age-related cognitive decline
"MND not only reinforces our dual-path business strategy but also provides an immediate opportunity for revenue growth and meaningful data collection," continued Rosén. "Investors can be excited about the implications of a consumer product directly supporting our pharmaceutical development pipeline."
Nugevia MND will be commercially available through direct-to-consumer e-commerce platforms starting Fall 2025 as a convenient two-capsule daily regimen.
A digital press kit, including high-resolution product imagery and key brand information, is available at https://ir.jupiterneurosciences.com/.
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia™ product line. Both efforts are powered by JOTROL™, Jupiter’s proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company’s prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson’s disease, includeing indications such as Alzheimer’s Disease, Mucopolysaccharidoses Type I, Friedreich’s Ataxia, and MELAS. More information may be found on the Company’s website www.jupiterneurosciences.com.
About JOTROL
Resveratrol is one of the world’s most extensively researched molecules. Thorough evaluation has shown that for the compound to be effective, it requires a high C-Max (~300 ng/ml of resveratrol in plasma), achievable only with doses exceeding 3 grams using earlier resveratrol products. Poor bioavailability has been a well-documented issue with resveratrol. Doses over 2 grams have been associated with severe gastrointestinal (GI) side effects, which have prevented the compound from receiving regulatory approval for any indication.
Jupiter Neurosciences (JUNS) conducted a Phase I study demonstrating that JOTROL™ achieves over nine times higher bioavailability compared to resveratrol used in earlier clinical trials (e.g., Turner et al., MCI/Early Alzheimer’s Disease trial, and Yui et al., Friedreich’s Ataxia trial). The results of this Phase I study, which will be cross-referenced in all upcoming JOTROL™ trials, were published in the Journal of Alzheimer’s Disease and AAPS Open in February 2022. JUNS is now advancing JOTROL™ toward a Phase IIa trial in Parkinson’s Disease.
In addition to its therapeutic applications, JOTROL™ serves as the foundation for Jupiter’s Nugevia™ consumer supplement line. By leveraging the same clinically validated delivery technology, Nugevia™ introduces pharmaceutical-grade bioavailability into the wellness space, offering targeted support for cognitive health, skin vitality, and cellular energy.
FORWARD-LOOKING STATEMENTS
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations, including the Company’s ability to generate revenues from the sale of JOTROL products to consumers through the DTC model. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct. The Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to read the risk factors contained in the Company’s final prospectus and other reports it files with the SEC before making any investment decisions regarding the Company’s securities. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Contact:
Dave Gentry
RedChip Companies, Inc.
1-407-644-4256
1-800-RED-CHIP (733-2447)
JUNS@redchip.com
FAQ
What is Jupiter Neurosciences' (JUNS) new Nugevia MND supplement?
When will Jupiter Neurosciences' (JUNS) Nugevia MND be available for purchase?
What are the key benefits of Jupiter Neurosciences' Nugevia MND supplement?
How does Nugevia MND fit into Jupiter Neurosciences' business strategy?
What is the target market size for Jupiter Neurosciences' Nugevia MND?
